The Medicines and Healthcare products Regulatory Agency said on Monday that it would aim to make a decision on Pfizer and BioNTech’s Covid-19 vaccine candidate “in the shortest time possible” after receiving additional data about the shot.
“It is our job now to rigorously assess these data and the evidence submitted on the vaccine’s safety, quality and effectiveness,” said June Raine, chief executive of the MHRA.
“As we have received this data through a rolling review, we have already started our analysis and will aim to make a decision in the shortest time possible, without compromising the thoroughness of our review.”
